News Column

EyeTechCare appoints Dietrich Wolf as chief executive officer; The new CEO intends to pursue market development in Europe and beyond

June 24, 2014

Rillieux-la-Pape, France - EyeTechCare SA, which develops non-invasive therapeutic medical devices for the ophthalmology market, today announces that it has appointed Dr Dietrich Wolf as the new chief executive officer. Wolf succeeds Fabrice Romano, co-founder, who remains a member of the board.

Dietrich Wolf joins the company with the view to establishing High Intensity Focused Ultrasound (HIFU) as a recognized future option in glaucoma care. The EyeOP1 device has been launched to select centers in France and neighboring countries for highly advanced refractory glaucoma. The next steps will include further roll out in Europe and preparation for overseas markets. EyeTechCare also plan to research the indication for less advanced glaucoma cases, to further increase the number of patients eligible for this new therapy.

Dietrich Wolf has a 15 year successful international track record in the medtech industry. He recently worked for Carl Zeiss Meditec, successfully ramping up a disruptive new technology in oncology, winning prestigious innovation awards in both Germany and the US. Prior to Zeiss, Wolf worked at different business divisions of Dentsply International in the field of dental implants and high tech ceramics. He holds a Master's degree and a PhD in Materials Science and Engineering from the University of Erlangen, Germany.

"I am delighted to join the highly successful team at EyeTechCare. The HIFU technology holds immense promise and I will continue working with our international clinical partners to take our device further through clinical development and to establish it as a new standard of care in glaucoma treatment" said Dietrich Wolf.

Bernard Gilly, chairman of the board said: "With Dietrich joining, EyeTechCare strengthens its team to enhance its commercial activities in Europe and to begin its US clinical development, confirming our ambition to become a leader in the field of glaucoma treatment. On behalf of the board of EyeTechCare, I would like to thank Fabrice Romano for his seminal contribution to the creation and development of this exciting technology over the past six years."

About EyeTechCare

EyeTechCare develops non-invasive therapeutic medical devices for the ophthalmology market based on High-Intensity Focused Ultrasound (HIFU).

The company's first device, EyeOP1(R), is for the treatment of glaucoma, a degenerative disease of the optic nerve often associated with an elevated intraocular pressure (IOP). Glaucoma affects about 4 per cent of the world population and can lead to blindness if the IOP is not controlled adequately over the entire life of the patient. The treatments offered up to now have been constructed around medication, lasers and surgery. None of these therapies provide a satisfactory balance between effectiveness and safety. EyeTechCare aims at closing this gap with its non-invasive device. EyeOP1 utilizes proprietary technology to inactivate parts of the tiny ciliary glands that produce the aqueous humor with utmost precision so as to decrease the IOP while preserving surrounding structures. EyeOP1 has been undergoing clinical trials for highly advanced glaucoma patients in France and Europe and is CE marked. Peer reviewed articles report a promising response rate for this challenging group of patients and a very favorable tolerance profile.

Based in Rillieux-la-Pape, near Lyon, France, EyeTechCare SA was founded in 2008 by three experienced managers with complementary expertise in the medical, industrial and regulatory fields.

For more information, go to

To view the original release:

Mark Tidmarsh


Tel UK: +44 1273 675100+44 1273 675100

Tel France: +33 1 56 54 07 00+33 1 56 54 07 00

Tel US: +1 617 517 0146+1 617 517 0146



For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: M2 PressWIRE

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters